Doxycycline treatment in mycoplasma and ureaplasma urinary tract infections

ABSTRACT

Mycoplasma hominis [M. hominis] and Urea plasma urealyticum [U. urealyticum] were documented to play a significant role in recurrent urinary tract infections [UTI] in Egyptian patients especially when associated with urinary schistosomiasis. Doxycycline is the drug of choice used to treat these infections at TBRI [100 mgtwice daily for 2 weeks] and this study was conducted to evaluate its efficacy. Fifty six patients with M. hominis and/or U. urealyticum UTI were included and classified into two groups according to association with urinary schistosomiasis. Cure rates of 39.4% and 34.8% were achieved after one course of treatment in group [I] [schistosomal] and in group [II] [non-schistosomal] patients respectively. Higher rates were achieved after a second course of doxycycline in resistant cases [88% and 91% respectively] Test-of-cure cultures obtained 10-15 days after completion of therapy showed treatment failure in only 6 patients [10.9%], four of them had urinary tract stones and their urine samples grew U. urealyticum, three of these patients were schistosomal. It is concluded that a high cure rate [89%] could be achieved by repeating the doxycycline course. Patients with urinary stones should be managed operatively before successful doxycycline therapy